CA2298102A1 - Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux - Google Patents

Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux Download PDF

Info

Publication number
CA2298102A1
CA2298102A1 CA002298102A CA2298102A CA2298102A1 CA 2298102 A1 CA2298102 A1 CA 2298102A1 CA 002298102 A CA002298102 A CA 002298102A CA 2298102 A CA2298102 A CA 2298102A CA 2298102 A1 CA2298102 A1 CA 2298102A1
Authority
CA
Canada
Prior art keywords
viral
gene
patient
host cell
resistance test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002298102A
Other languages
English (en)
Inventor
Daniel J. Capon
Jeannette M. Whitcomb
Neil T. Parkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2298102A1 publication Critical patent/CA2298102A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé permettant de déterminer la sensibilité à un médicament antiviral dirigé contre le virus de l'hépatite C (VHC) ou le cytomégalovirus humain (CMVH), procédé qui consiste: (a) à introduire dans une cellule hôte un vecteur d'évaluation de la résistance comprenant un segment dérivé du patient et un gène indicateur; (b) à cultiver la cellule hôte de (a); (c) à mesurer l'expression du gène indicateur dans une cellule hôte cible; et (d) à comparer l'expression du gène indicateur en (c) avec l'expression du gène indicateur mesurée lorsque les opérations (a)-(c) sont réalisées en l'absence du médicament antiviral, une concentration d'essai du médicament antiviral etant présente lors des opérations (a)-(c); des opérations (b)-(c); ou de l'opération (c). L'invention concerne également un procédé destiné à déterminer la résistance d'un patient à un médicament antiviral dirigé contre VHC ou CMVH, lequel procédé consiste: (a) à déterminer la sensibilité du patient au médicament antiviral à un moment donné en utilisant le test de sensibilité précité, le segment dérivé du patient étant obtenu vers ce moment-là; (b) à déterminer la sensibilité du même patient au médicament antiviral quelque temps plus tard; et (c) à comparer les sensibilités au médicament antiviral déterminées en (a) et (b), étant entendu qu'une diminution de la sensibilité au médicament antiviral mesurée dans l'intervalle de temps écoulé indique le développement ou la progression de la résistance du patient au médicament antiviral. Cette invention a, en outre, pour objet un procédé permettant d'évaluer l'efficacité biologique d'un composé candidat de médicament dirigé contre les virus VCH ou CMVH. L'invention concerne enfin des compositions renfermant des vecteurs d'évaluation de la résistance, comprenant un segment dérivé d'un patient comprenant à son tour un gène de VHC ou de CMVH et un gène indicateur, ainsi que des cellules hôtes transformées par les vecteurs d'évaluation de la résistance.
CA002298102A 1997-07-30 1998-07-30 Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux Abandoned CA2298102A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90350797A 1997-07-30 1997-07-30
US08/903,507 1997-07-30
PCT/US1998/015967 WO1999006597A1 (fr) 1997-07-30 1998-07-30 Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux

Publications (1)

Publication Number Publication Date
CA2298102A1 true CA2298102A1 (fr) 1999-02-11

Family

ID=25417619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002298102A Abandoned CA2298102A1 (fr) 1997-07-30 1998-07-30 Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux

Country Status (6)

Country Link
EP (1) EP1012334A4 (fr)
JP (1) JP2001512036A (fr)
KR (1) KR20010022420A (fr)
AU (1) AU8897698A (fr)
CA (1) CA2298102A1 (fr)
WO (1) WO1999006597A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739645D1 (de) * 1996-01-29 2009-12-17 Monogram Biosciences Inc Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
AU7268000A (en) * 1999-07-21 2001-02-13 Martin Heinkelein Method for quantization of the antiviral effect of antiviral active principles
ES2334011T3 (es) * 2000-06-08 2010-03-04 Virco Bvba Metodo para predecir la resistencia a los agentes terapeuticos utilizando redes neurales.
DK2014671T3 (da) * 2002-03-11 2010-09-20 Lab 21 Ltd Fremgangsmåder og sammensætninger til identificering og karakterisering af hepatitis C
EP1454988A1 (fr) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pseudo-particules du flavivirus infectieuses contenant des protéines prM-E d'enveloppe
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
EP2527474A1 (fr) 2006-10-20 2012-11-28 Innogenetics N.V. Méthodologie d'analyse des variations de séquence dans la zone génomique HCV NS3/4A
WO2013082617A1 (fr) * 2011-12-02 2013-06-06 Laboratory Corporation Of America Holdings Méthodes de détection phénotypique de sous-populations résistantes à un inhibiteur du vhc
CN113299340B (zh) * 2021-06-09 2023-06-30 四川大学华西医院 靶标试验药物的筛选方法、靶标试验药物筛选器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (fr) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Lignes de cellules humaines stables exprimant un produit de gène indicateur sous des contrôles génétiques specifiques à un virus
ATE310817T1 (de) * 1992-09-28 2005-12-15 Chiron Corp Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
AU1923795A (en) * 1994-02-18 1995-09-04 University Of Washington Methods and compositions for screening for anti-aids drugs
EP0877937B1 (fr) * 1996-01-26 2002-05-22 Virco N.V. Procede pour evaluer la chimiotherapie de patients seropositifs vih base sur la sensibilite medicamenteuse phenotypique de la souche vih du patient
DE69739645D1 (de) * 1996-01-29 2009-12-17 Monogram Biosciences Inc Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening

Also Published As

Publication number Publication date
KR20010022420A (ko) 2001-03-15
WO1999006597A1 (fr) 1999-02-11
JP2001512036A (ja) 2001-08-21
EP1012334A4 (fr) 2004-12-29
AU8897698A (en) 1999-02-22
EP1012334A1 (fr) 2000-06-28

Similar Documents

Publication Publication Date Title
US6942969B2 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20070099296A1 (en) Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US7919312B2 (en) Self-replicating RNA molecule from hepatitis C virus
Appel et al. Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A
Fischl et al. High-throughput screening using dengue virus reporter genomes
EP1170380B1 (fr) Méthodes déterminant une susceptibilité et résistance anti-virale et screening pour des agents anti-viraux
US20020034732A1 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
Karamichali et al. HCV defective genomes promote persistent infection by modulating the viral life cycle
CA2298102A1 (fr) Compositions et procedes permettant de determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux, et criblage de medicaments antiviraux
JP2016515378A (ja) ウイルス阻害剤に対するウイルス感受性を決定するための方法
CA2601922C (fr) Procedes et compositions pour la determination de la sensibilite et de la capacite de replication de hiv de medicament anti-vih
CA2437072A1 (fr) Systeme in vitro pour la replication de virus a arn polymerase arn dependante
EP1499727A1 (fr) Replicon de virus de l'hepatite c contenant un gene rapporteur et un marqueur de selection
AU776535B2 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO2004092402A1 (fr) Methodologie combinant deux genes rapporteurs et une reduction colorimetrique pour evaluer l'activite antivirale et la cytotoxicite d'inhibiteurs du virus de l'hepatite c
AU2002240214A1 (en) In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead